Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.

Shargian, Liat; Raanani, Pia; Yeshurun, Moshe; Gafter-Gvili, Anat; Gurion, Ronit

Shargian, Liat; Raanani, Pia; Yeshurun, Moshe; Gafter-Gvili, Anat; Gurion, Ronit.

Affiliation

Shargian L; Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.
Raanani P; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yeshurun M; Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.
Gafter-Gvili A; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Gurion R; Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.

Br J Haematol ; 198(5): 838-846, 2022 09.

Article in En | MEDLINE | ID: mdl-35765220

Subject(s)

Hematopoietic Stem Cell Transplantation; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Receptors, Chimeric Antigen; Antigens, CD19; Humans; Immunotherapy, Adoptive/methods; Lymphoma, Large B-Cell, Diffuse/etiology; Lymphoma, Large B-Cell, Diffuse/therapy; Neoplasm Recurrence, Local/therapy; Receptors, Antigen, T-Cell; Standard of Care; Transplantation, Autologous

Key words

B-cell; CAR-T; CD19 chimeric antigen receptor; diffuse large cell; lymphoma; meta-analysis; relapse: refractory

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy, Adoptive / Lymphoma, Large B-Cell, Diffuse / Hematopoietic Stem Cell Transplantation / Receptors, Chimeric Antigen Type of study: Clinical_trials / Etiology_studies / Systematic_reviews Limits: Humans Language: En Journal: Br J Haematol Year: 2022 Type: Article Affiliation country: Israel

Fulltext

XML

PubMed Links

Search on Google